Though long-term prospects appear sound, near-term earnings visibility remains limited for Dr. Reddy’s Labs, Cipla, and Lupin, whereas Sun Pharma stands out due to its stronger visibility and specialty-led growth.
Though long-term prospects appear sound, near-term earnings visibility remains limited for Dr. Reddy’s Labs, Cipla, and Lupin, whereas Sun Pharma stands out due to its stronger visibility and specialty-led growth.